Role of Lung Function for Exercise Capacity in Well-trained Individuals

Launched by MORTEN HOSTRUP, PHD · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how different medications may affect exercise performance in physically active individuals. Specifically, the study will explore the impact of inhaling two combinations of medications—vilanterol with fluticasone furoate and indacaterol with mometasone furoate—on how well people can perform during exercise. The goal is to understand how lung function influences exercise capacity in healthy, well-trained adults.

To qualify for this study, participants should be between 18 and 39 years old, exercise regularly (at least 5 hours a week), and have a high level of oxygen consumption. However, those with severe asthma, certain heart problems, significant lung function issues, or who are pregnant or smokers will not be eligible. If you join the study, you can expect to participate in assessments that measure your exercise performance and lung function while using the study medications. This research could provide valuable insights into how to enhance exercise capabilities in fit individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-39
• • Physically active \> 5 h weekly
• • Maximal oxygen consumption classified as high or very high
• Exclusion Criteria:
• • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
• • ECG abnormality
• • ACQ score \> 1.5
• • Severe bronchial hyperreactivity as determined by mannitol test
• • FEV1/FVC ratio \< 0.7 determined with spirometry
• • Chronic illness determined to be a potential risk for participant during study
• • In chronic treatment with medication that may interfere with study results
• • Pregnancy
• • Smoker
• • Blood donation during the past 3 months